EURETINA 2024: Andrea Govetto, MD, PhD, says it takes teamwork to understand macular oedema

News
Video

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

On the opening day of the European Society of Retina Specialists (EURETINA) meeting, Andrea Govetto, MD, PhD, received the inaugural Ramin Tadayoni Award. Then he visited the Ophthalmology Times Europe booth to discuss his wonderful research team, the things we fail to understand about diabetic macular oedema and what makes EURETINA a must-see conference.

Editor's note: The below transcript has been lightly edited for clarity.

Andrea Govetto, MD, PhD: Hello. I'm Andrea Govetto. I'm a VR surgeon at the Humanitas University in Milan, and I'm here at EURETINA as a presenter in the faculty.

I'm honored to receive the [Ramin Tadayoni] award. The project is very cool, actually. It's a computational model of fluid flow in macular oedema.

So macular oedema is something that many people think is obvious, but is not, because we actually don't know why the cysts form where they are located and why they persist in some cases. So the engineers, because I don't know anything about mathematics—the award will go to pay the engineers to explain, to make a mathematical simulation and explain me why the cysts in macular oedema form, and why so specifically in the macula, which is a very particular part of the retina. My guess is that the morphology of the cell there plays a key role in the formation of the oedema.

You know, nobody likes to work for free, so it's important to reward the work of others. So, I work with a beautiful team. My chief is Mario Romano, who is also presenting here at EURETINA, and I work with two very talented engineers, which are Alessia Ruffini from Genoa and Rodolfo Repetto from Genoa. The bulk of work for the mathematics is on them. So, these funds will go, partially, to pay them for their great work. It's a way to reward what they are doing because until now, they’ve worked for free, basically.

So, specifically, epiretinal membranes and the laminar macular holes. Actually, tomorrow, we have a very great session, with, ESASO and FLORETINA on laminar macular holes. A lot of very good presenters will be there, me as well. So it will be fun and interesting to see.

And then I have a course, which we did also last year at EURETINA, purely focused on the epiretinal membrane, and I will speak, specifically, about the pathophysiology and the classification of an epiretinal membrane that we developed in these years. So I think it would be very interesting to attend.

The most interesting thing about this meeting is connections. I'm lucky, because I know many people around the globe, and many of them are coming here to Barcelona. So it's a way to see my friends that live abroad in South America, in Argentina, in the US, in Japan. So I like very much the connections that you can make here in EURETINA.

Recent Videos
Ricardo Letião Guerra, MD, MSc, FICO, speaks with Hattie Hayes of Ophthalmology Times Europe
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
Related Content
© 2024 MJH Life Sciences

All rights reserved.